Increased levels of 17-hydroxyprogesterone (17-OHP) in MASLD is due to the aberrant expression of cytochrome P450 17A1 (CYP17A1) which stimulates gluconeogenesis through a glucocorticoid receptor-dependent pathway. Here, CYP17A1 is linked to metabolic dysfunction-associated steatotic liver disease.